Jazz Pharmaceuticals plc (JAZZ) earnings date, results and what the price requires

    Nasdaq · SEC CIK 0001232524 · SEC filings checked Oct 17, 2026

    Next report
    Nov 3, 2026
    Estimated from reporting history (92-day cycle, SEC 8-K item 2.02 results filings). Not confirmed.
    Last close
    $214.42
    Polygon.io daily close, Oct 15, 2026. End of day, not live.
    Trailing diluted EPS
    $14.63
    Sum of quarters ending Jun 30, 2026, Mar 31, 2026, Dec 31, 2025, Sep 30, 2025 · P/E 14.7

    Previous results (SEC filings)

    Quarter endedReportedRevenueNet incomeDiluted EPSSource
    Jun 30, 2026Aug 3, 2026$1.21B$192.8M$2.78Filing
    Mar 31, 2026May 5, 2026$1.07B$293.1M$4.43Filing
    Dec 31, 2025Jan 12, 2026$1.20B$203.4M$3.34Filing
    Sep 30, 2025Nov 5, 2025$1.13B$251.4M$4.08Filing
    Jun 30, 2025Aug 5, 2025$1.05B$-718.5M$-11.74Filing
    Mar 31, 2025May 6, 2025$897.8M$-92.5M$-1.52Filing
    Dec 31, 2024Jan 13, 2025$1.09B$191.1M$2.97Filing
    Sep 30, 2024Nov 6, 2024$1.05B$215.1M$3.42Filing

    What would Jazz Pharmaceuticals plc have to report for its valuation to change?

    At $214.42, with a 9.0% required return and a 18× earnings multiple in 5 years, earnings per share must grow about 4.6% a year, to $18.33. On that path the next quarter needs diluted EPS near $4.27, against $4.08 in the quarter ended Sep 30, 2025.

    Are you considering buying, or do you already own shares?

    Compare buying at the last close now with waiting for results: if the report moves the growth the price requires, the entry price you would accept changes with it.

    ResultOriginalYours
    Required EPS growth / year4.6%4.6%
    EPS needed in final year$18.33$18.33

    Changed: nothing yet. Model: EPS × (1+g)^years × final P/E, discounted at the required return, equals today's price. Inputs: SEC diluted EPS and the dated close above.

    Prepare for earnings across my investments — $399/month

    Keep working models for the companies you follow, compare your expectations with reported results, and review what changes your investment decision. JAZZ goes in with your buy-or-wait comparison and assumptions preserved.

    Start Desk — $399/month

    Figures come from SEC EDGAR XBRL filings. Dates marked "estimated" are calculated from the company's past results filings and are not confirmed. Not investment advice.